**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 74587

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Effectiveness and safety of chemotherapy for patients with malignant gastrointestinal obstruction: A Japanese population-based cohort study**

Fujisawa G *et al*. Chemotherapy for malignant gastrointestinal obstruction patients

Gota Fujisawa, Ryota Niikura, Takuya Kawahara, Tetsuro Honda, Kenkei Hasatani, Naohiro Yoshida, Tsutomu Nishida, Tetsuya Sumiyoshi, Shu Kiyotoki, Takashi Ikeya, Masahiro Arai, Yoku Hayakawa, Takashi Kawai, Mitsuhiro Fujishiro

**Gota Fujisawa, Yoku Hayakawa, Mitsuhiro Fujishiro,** Department of Gastroenterology, Graduate school of Medicine, The University of Tokyo, Tokyo 1138655, Japan

**Ryota Niikura, Takashi Kawai**, Gastroenterological Endoscopy, Tokyo Medical University, Tokyo 1600023, Japan

**Takuya Kawahara,** Clinical Research Support Center, The University of Tokyo Hospital, Tokyo 1138655, Japan

**Tetsuro Honda,** Department of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 8508555, Japan

**Kenkei Hasatani,** Department of Gastroenterology, Fukui Prefectural Hospital, Fukui 9108526, Japan

**Naohiro Yoshida,** Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Ishikawa 9208530, Japan

**Tsutomu Nishida,** Department of Gastroenterology, Toyonaka Municipal Hospital, Osaka 5608565, Japan

**Tetsuya Sumiyoshi,** Department of Gastroenterology, Tonan Hospital, Hokkaido 0600004, Japan

**Shu Kiyotoki,** Department of Gastroenterology, Shuto General Hospital, Yamaguchi 7420032, Japan

**Takashi Ikeya,** Department of Gastroenterology, St. Luke's International Hospital, Tokyo 1048560, Japan

**Masahiro Arai,** Department of Gastroenterology, Nerima Hikarigaoka Hospital, Tokyo 1790072, Japan

**Author contributions:** All authors contributed to the acquisition of data for this study; Fujisawa G analyzed the data and wrote the draft manuscript; Niikura R designed the research study; Kawahara T contributed data analysis; Honda T, Hasatani K, Yoshida N, Nishida T, Sumiyoshi T, Kiyotoki S, Ikeya T, Arai M, Hayakawa Y, Kawai T, and Fujishiro M performed the research; All authors have read and approved the final manuscript.

**Supported by** the Tokyo Medical University Cancer Research Foundation, No. 2021; and KAKENHI Grants-in-Aid for Scientific Research, No. 20K08375.

**Corresponding author: Ryota Niikura, MD, PhD, Adjunct Associate Professor, Doctor,** Gastroenterological Endoscopy, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 1600023, Japan. rniikura@triton.ocn.ne.jp

**Received:** December 30, 2021

**Revised:** March 9, 2022

**Accepted:** April 22, 2022

**Published online:** June 6, 2022

**Abstract**

BACKGROUND

The impacts of chemotherapy on patients with malignant gastrointestinal obstructions remain unclear, and multicenter evidence is lacking.

AIM

To evaluate the effectiveness and safety of chemotherapy in patients with unresectable malignant gastrointestinal obstructions.

METHODS

We conducted a multicenter retrospective cohort study that compared the chemotherapy group who received any chemotherapeutics after interventions, including palliative surgery or self-expandable metal stent placement, for unresectable malignant gastrointestinal obstruction *vs* the best supportive care (BSC) group between 2014 and 2019 in nine hospitals. The primary outcome was overall survival, and the secondary outcomes were patency duration and adverse events, including gastrointestinal perforation and gastrointestinal bleeding.

RESULTS

In total, 470 patients in the chemotherapy group and 652 patients in the BSC group were analyzed. During the follow-up period of 54.1 mo, the median overall survival durations were 19.3 mo in the chemotherapy group and 5.4 mo in the BSC group (log-rank test, *P* < 0.01). The median patency durations were 9.7 mo [95% confidence interval (CI): 7.7-11.5 mo] in the chemotherapy group and 2.5 mo (95%CI: 2.0-2.9 mo) in the BSC group (log-rank test, *P* < 0.01). The perforation rate was 1.3% (6/470) in the chemotherapy group and 0.9% (6/652) in the BSC group (*P* = 0.567). The gastrointestinal bleeding rate was 1.5% (7/470) in the chemotherapy group and 0.5% (3/652) in the BSC group (*P* = 0.105).

CONCLUSION

Chemotherapy after interventions for unresectable malignant gastrointestinal obstruction was associated with increased overall survival and patency duration.

**Key Words:** Gastrointestinal cancer; Chemotherapy; Malignant gastrointestinal obstruction; Self-expandable metal stent; Palliative surgery

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Fujisawa G, Niikura R, Kawahara T, Honda T, Hasatani K, Yoshida N, Nishida T, Sumiyoshi T, Kiyotoki S, Ikeya T, Arai M, Hayakawa Y, Kawai T, Fujishiro M. Effectiveness and safety of chemotherapy for patients with malignant gastrointestinal obstruction: A Japanese population-based cohort study. *World J Clin Cases* 2022; 10(16): 5253-5265

**URL**: https://www.wjgnet.com/2307-8960/full/v10/i16/5253.htm

**DOI**: https://dx.doi.org/10.12998/wjcc.v10.i16.5253

**Core Tip:** The impacts of chemotherapy on patients with malignant gastrointestinal obstructions remain unclear, and multicenter evidence is lacking. Does chemotherapy improve the duration of gastrointestinal patency (and thus overall survival) in such patients? This multicenter observational study revealed that the median patency duration in the chemotherapy group was longer than that in the best supportive care group (9.7 *vs* 2.5 mo). Similarly, the median overall survival was longer in the chemotherapy than the best supportive care group (19.3 *vs* 5.4 mo, log-rank test, *P* < 0.01).

**INTRODUCTION**

Malignant gastrointestinal obstruction is an important issue in advanced cancer and occurs in approximately 30% of patients with gastrointestinal cancer[1]. Gastrointestinal obstruction causes oral intake impairment, nausea, vomiting, and abdominal pain and also poses a risk of gastrointestinal perforation. Primary therapy involves fasting, intravenous hydration, and nasogastric tube or ileus tube placement for bowel rest and decompression[2,3]. In secondary therapy, complete surgical resection is performed for resectable malignant gastrointestinal obstruction; palliative surgery, including bypass and stoma surgery or self-expandable metal stent (SEMS) placement, is performed at one or more points of unresectable malignant gastrointestinal obstruction (Figure 1).

Chemotherapy after palliative surgery or SEMS placement is a particularly challenging clinical issue. Although it can improve overall survival[4-6], little is known regarding the difference in overall survival between patients undergoing chemotherapy treatment and those receiving best supportive care (BSC). In addition, the risk of gastrointestinal perforation is a concern for treatment involving chemotherapy combined with SEMS[7,8]. However, previous studies on the safety of chemotherapy in this situation were limited by small sample sizes.

We performed a large multicenter cohort study to evaluate the effectiveness and safety of chemotherapy after palliative surgery or SEMS placement compared with BSC in patients with unresectable malignant gastrointestinal obstructions. In addition, we aimed to identify the optimal population for chemotherapy after palliative surgery or SEMS placement.

**MATERIALS AND METHODS**

***Study design, setting, and participants***

We performed a retrospective cohort study using the diagnostic procedure combination (DPC) databases of nine hospitals between January 2014 and March 2019. The combined database comprised the records of all inpatients and outpatients at the University of Tokyo Hospital, Shuto General Hospital, Fukui Prefectural Hospital, Nerima Hikarigaoka Hospital, St. Luke’s International Hospital, Toyonaka Municipal Hospital, Ishikawa Prefectural Central Hospital, and Nagasaki Minato Medical Center and of inpatients at Tonan Hospital. The database included diagnoses, comorbidities, and adverse events using the International Classification of Diseases, 10th revision and Japanese original disease codes. It also included the cancer stage according to the Union for International Cancer Control classification system[9], Japanese original medication and procedure codes, and Barthel index (BI)[10].

From the database, we identified patients who had undergone palliative surgery or SEMS placement for gastrointestinal obstruction, including esophageal bypass surgery, gastrojejunostomy, duodenojejunostomy, intestinal bypass surgery, stoma surgery, esophageal stenting, gastroduodenal stenting, or colonic stenting, who did not undergo gastrointestinal tract resection thereafter. We excluded patients without malignant disease, those with a history of gastrointestinal perforation or fistula, and patients with multifocal gastrointestinal obstructions. The codes used for patient selection are listed in Supplementary Table 1.

We selected the chemotherapy group (patients who received any chemotherapy drugs after the intervention) with the BSC group (patients who did not receive chemotherapy drugs after the intervention) (Figure 1). The follow-up period was from the date of the intervention to death or the final visit. The end of follow-up was March 2019, and loss to follow-up was defined as the date of the final visit. The study was approved by the Institutional Review Board of the University of Tokyo Hospital (No. 2019161NI).

***Outcomes and variables***

The primary outcome was overall survival. The secondary outcomes were patency duration and adverse events, including perforation and gastrointestinal bleeding. Patency duration was defined as the time between the first food intake after the intervention and reintervention, stopping food intake, or death. Perforation was defined as surgery for suture, drainage, or intra-abdominal lavage. Gastrointestinal bleeding was defined as any gastrointestinal bleeding requiring endoscopic hemostasis. The procedure codes for outcomes are listed in Supplementary Table 2.

We evaluated the following clinical factors: Age, sex, comorbidities, BI, medication use, cancer type, cancer stage, obstruction site, chemotherapy before the intervention, and intervention type. Age was categorized into < 75 years and ≥ 75 years. Comorbidities were evaluated by the Charlson comorbidity index (CCI)[11] and categorized as < 3 and ≥ 3. BI was categorized as ≥ 60, < 60, and missing. We evaluated the use of aspirin, thienopyridine, warfarin, direct oral anticoagulants (including dabigatran, rivaroxaban, apixaban, and edoxaban), other antiplatelet drugs (including dilazep hydrochloride hydrate, dipyridamole, trapidil, cilostazol, limaprost alfadex, ethyl icosapentate, beraprost sodium, sarpogrelate hydrochloride, and ozagrel sodium), nonsteroidal anti-inflammatory drugs, and steroids. The cancer type was categorized into esophageal cancer, gastric cancer, pancreatic cancer, colorectal cancer, and other cancers. The cancer stage was categorized into stage I–III, stage IV or recurrence, and missing. The obstruction site was categorized as esophageal obstruction, gastroduodenal obstruction, or lower gastrointestinal obstruction. The intervention type was categorized as palliative surgery or SEMS placement. The International Classification of Diseases, 10th revision codes of primary cancers and comorbidities are listed in Supplementary Table 3, and the medication codes are shown in Supplementary Table 4.

***Statistical analysis***

Overall survival and patency durations were estimated by the Kaplan–Meier method and were compared by log-rank test. Data were censored at the date of the final visit. Univariate Cox proportional hazards models were used to estimate crude hazard ratios and 95% confidence intervals (CIs). The multivariate Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) using age, sex, cancer type, cancer stage, CCI, BI, and intervention type.

Categorical data were compared by the chi-squared test or Fisher’s exact test and continuous data by the Wilcoxon rank-sum test. A *P-*value < 0.05 was considered indicative of statistical significance. Statistical analysis was performed using SAS software v. 9.4 (SAS Institute, Cary, NC, United States).

**RESULTS**

***Patient characteristics***

Fourteen hundred forty patients who had undergone palliative surgery or SEMS placement for unresectable gastrointestinal obstruction were extracted from the DPC database. After excluding patients without malignant disease (*n* = 234), those with a history of gastrointestinal perforation or fistula (*n* = 74), and patients with multifocal gastrointestinal obstructions (*n* = 10), the remaining 1122 patients were analyzed. In total, 470 patients who received chemotherapy drugs after the intervention (chemotherapy group) and 652 patients who did not receive chemotherapy drugs after the intervention (BSC group) were analyzed (Figure 2). The patients’ baseline characteristics are listed in Table 1. The age, CCI, BI, medication, cancer type, and cancer stage distributions were significantly different between the groups. The chemotherapy group had higher rates of < 75 aged patients, CCI ≥ 3, BI ≥ 60, and stage IV or recurrence.

***Overall survival and patency duration***

During the follow-up period of 54.1 mo, the median overall survival durations were 19.3 mo (95%CI: 16.2-25.9 mo) in the chemotherapy group and 5.4 mo (95%CI: 3.6-7.6 mo) in the BSC group (log-rank test, *P* < 0.01; Figure 2). The median patency durations were 9.7 mo (95%CI: 7.7-11.5 mo) in the chemotherapy group and 2.5 mo (95%CI: 2.0-2.9 mo) in the BSC group (log-rank test, *P* < 0.01; Figure 3).

***Factors affecting overall survival and patency duration***

The factors affecting overall survival are shown in Table 2. Multivariate analysis showed that the factors affecting overall survival were chemotherapy after the intervention (aHR, 0.36), CCI ≥ 3 (aHR, 1.56), BI < 60 (aHR, 2.04), gastric cancer compared with esophageal cancer (aHR, 0.64), colorectal cancer compared with esophageal cancer (aHR, 0.47), stage IV or recurrence compared with stage I–III (aHR, 1.79), chemotherapy before the intervention (aHR, 1.66), and SEMS placement compared with palliative surgery (aHR, 1.63).

The factors affecting patency are shown in Table 3. Multivariate analysis showed that the factors affecting patency duration were chemotherapy after the intervention (aHR, 0.49), CCI ≥ 3 (aHR, 1.41), BI < 60 (aHR, 1.55), colorectal cancer *vs* esophageal cancer (aHR, 0.67), stage IV or recurrence compared with stage I–III (aHR, 1.65), chemotherapy before the intervention (aHR, 1.64), and SEMS placement compared with palliative surgery (aHR, 2.48).

The results of a subgroup analysis of adjusted HRs for overall survival and patency duration were consistent with those of the overall analysis (Table 4).

***Adverse events***

The rates of adverse events are listed in Table 5. The perforation rate was 1.3% (6/470) in the chemotherapy group (3 gastric cancers, one colorectal cancer, 1 breast cancer, and 1 unclassifiable cancer) and 0.9% (6/652) in the BSC group (3 colorectal cancers, 2 gastric cancers, and 1 esophageal cancer) (*P* = 0.567). In 4 of the 6 perforation cases in the chemotherapy group, perforation occurred a mean of 137 d after chemotherapy initiation.

The gastrointestinal bleeding rate was 1.5% (7/470) in the chemotherapy group (4 gastric cancers, 1 esophageal cancer, 1 pancreatic cancer, and o1colorectal cancer) and 0.5% (3/652) in the BSC group (1 esophageal cancer and 2 pancreatic cancers) (*P* = 0.105). In 4 of 7 bleeding cases in the chemotherapy group, gastrointestinal bleeding occurred a mean of 294 d after chemotherapy initiation.

**DISCUSSION**

Chemotherapy after palliative surgery or SEMS placement for unresectable malignant gastrointestinal obstruction was associated with improved overall survival and patency duration and not associated with increased perforation or gastrointestinal bleeding compared with BSC. In addition, its effectiveness for overall survival and patency duration was consistent among cancer types and obstruction sites.

The chemotherapy group showed longer overall survival and patency durations. We suggest three reasons for these findings. First, chemotherapy drugs may prolong overall survival and patency duration even in patients with malignant gastrointestinal obstruction. We performed a multivariate analysis to reduce the influence of confounders; chemotherapy after the intervention was an independent factor for overall survival and patency duration. Previous studies reported similar results. Nomoto *et al*[6] reported that chemotherapy after bypass surgery for esophageal cancer improved the prognosis. Cho *et al*[4] showed that chemotherapy after SEMS placement for gastric cancer was a significant prognostic factor for patency duration. Ahn *et al*[5] reported that chemotherapy after palliative surgery or SEMS placement for colorectal cancer significantly improved survival. Second, bias in terms of patient characteristics may have influenced the results. The chemotherapy group included younger patients, those of higher BI, and more nonsteroidal anti-inflammatory drugs users. This suggests that the chemotherapy group may have previously been treated for other diseases. In turn, this may have increased palliative surgery performance and improved the patency and survival durations. Third, chemotherapy was not associated with increased perforation, which is a fatal complication. The risk of gastrointestinal perforation after SEMS placement is a matter of great concern, particularly when chemotherapy is combined with SEMS. The 2019 clinical guidelines of the Japanese Society for Cancer of the Colon and Rectum[2] does not recommend SEMS placement for patients with colonic obstruction who are indicated for systemic chemotherapy. However, available data on the safety of chemotherapy after palliative surgery or SEMS placement are limited. In this study, the rate of perforation was < 2% in the chemotherapy and BSC groups; however, the definition of perforation was major perforation that required surgery.

We performed a subgroup analysis to identify the optimal population for chemotherapy because this study included heterogenous patients with various cancers and obstruction sites, which could influence the effectiveness of chemotherapy. The effectiveness of chemotherapy after the intervention for overall survival and patency duration was consistent among the cancer types and obstruction sites. Especially in cases of pancreatic cancer and gastroduodenal obstruction, chemotherapy might be more beneficial. The effectiveness of chemotherapy after the intervention was similar among the cancer types and obstruction sites. Especially in cases of pancreatic cancer and gastroduodenal obstruction, chemotherapy may be more beneficial. These findings will help guide future research on treatment approaches and precision medicine. Currently, overall survival and recurrence risk are predicted based on limited data such as pathological findings. However, recent biological research has suggested potential biomarkers, including circulating tumor DNA and micro-RNA, as well as microbiome profiling, to predict overall survival and recurrence. In the near future, these precision medicine methods are expected to contribute to cancer therapies including molecular targeted anti-cancer drugs, monoclonal antibody therapy, and antibiotic therapies.

To our knowledge, this is the first study of the effectiveness and safety of chemotherapy after palliative surgery or SEMS placement for various types of unresectable malignant gastrointestinal obstruction. In addition, our finding showed that chemotherapy was associated with prolongs gastrointestinal patency. However, this study has several limitations. First, it was a retrospective study. Although we used multivariate Cox proportional hazard models to reduce the effects of confounding factors, some bias may remain because the decision to undergo chemotherapy depends on so many factors including unmeasured confounders. It is difficult to evaluate the effect of chemotherapy more accurately in our setting. Second, our study included patients with different types of cancer, and there were different numbers of patients among the cancer groups. Third, the DPC database lacked information on potential prognostic factors such as radiotherapy history and pathological findings.

**CONCLUSION**

In conclusion, chemotherapy after palliative surgery or SEMS placement for unresectable malignant gastrointestinal obstruction was associated with increased overall survival and patency duration independent of the cancer type and obstruction site, and it was not associated with an increased rate of gastrointestinal perforation.

**ARTICLE HIGHLIGHTS**

***Research background***

Malignant gastrointestinal obstruction is an important issue in advanced cancer and occurs in approximately 30% of patients with gastrointestinal cancer. Gastrointestinal obstruction causes oral intake impairment, nausea, vomiting, and abdominal pain and increases the risk of gastrointestinal perforation. Primary therapy involves fasting and decompression, and subsequently complete surgical resection is performed for resectable malignant gastrointestinal obstruction; palliative surgery includes bypass and stoma surgery or self-expandable metal stent (SEMS) placement.

***Research motivation***

The impacts of chemotherapy on patients with malignant gastrointestinal obstructions remain unclear, and multicenter evidence is lacking.

***Research objectives***

We performed a large multicenter cohort study to evaluate the effectiveness and safety of chemotherapy after palliative surgery or SEMS placement compared with best supportive care (BSC) in patients with unresectable malignant gastrointestinal obstructions. In addition, we aimed to identify the optimal population for chemotherapy after palliative surgery or SEMS placement.

***Research methods***

We conducted a multicenter retrospective cohort study that compared the chemotherapy group who received any chemotherapeutics after interventions, including palliative surgery or self-expandable metal stent placement, for unresectable malignant gastrointestinal obstruction *vs* BSC group between 2014 and 2019 in nine hospitals. The primary outcome was overall survival, and the secondary outcomes were patency duration and adverse events, including gastrointestinal perforation and gastrointestinal bleeding.

***Research results***

In total, 470 patients in the chemotherapy group and 652 patients in the BSC group were analyzed. During the follow-up period of 54.1 mo, the median overall survival durations were 19.3 mo in the chemotherapy group and 5.4 mo in the BSC group (log-rank test, *P* < 0.01). The median patency durations were 9.7 mo [95% confidence interval (CI): 7.7-11.5 mo] in the chemotherapy group and 2.5 mo (95%CI: 2.0-2.9 mo) in the BSC group (log-rank test, *P* < 0.01). The perforation rate was 1.3% (6/470) in the chemotherapy group and 0.9% (6/652) in the BSC group (*P* = 0.567). The gastrointestinal bleeding rate was 1.5% (7/470) in the chemotherapy group and 0.5% (3/652) in the BSC group (*P* = 0.105).

***Research conclusions***

Chemotherapy after interventions for unresectable malignant gastrointestinal obstruction was associated with increased overall survival and patency duration.

***Research perspectives***

Our results showed that chemotherapy may be more beneficial in cases of pancreatic cancer and gastroduodenal obstruction. These findings will help guide future research on treatment approaches and precision medicine. In the near future, these precision medicine methods are expected to contribute to cancer therapies including molecular targeted anti-cancer drugs, monoclonal antibody therapy, and antibiotic therapies.

**REFERENCES**

1 **Cousins SE**, Tempest E, Feuer DJ. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. *Cochrane Database Syst Rev* 2016: CD002764 [PMID: 26727399 DOI: 10.1002/14651858.CD002764.pub2]

2 **Hashiguchi Y**, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. *Int J Clin Oncol* 2020; **25**: 1-42 [PMID: 31203527 DOI: 10.1007/s10147-019-01485-z]

3 **van Hooft JE**, Veld JV, Arnold D, Beets-Tan RGH, Everett S, Götz M, van Halsema EE, Hill J, Manes G, Meisner S, Rodrigues-Pinto E, Sabbagh C, Vandervoort J, Tanis PJ, Vanbiervliet G, Arezzo A. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020. *Endoscopy* 2020; **52**: 389-407 [PMID: 32259849 DOI: 10.1055/a-1140-3017]

4 **Cho YK**, Kim SW, Hur WH, Nam KW, Chang JH, Park JM, Lee IS, Choi MG, Chung IS. Clinical outcomes of self-expandable metal stent and prognostic factors for stent patency in gastric outlet obstruction caused by gastric cancer. *Dig Dis Sci* 2010; **55**: 668-674 [PMID: 19333756 DOI: 10.1007/s10620-009-0787-3]

5 **Ahn HJ**, Kim SW, Lee SW, Lee SW, Lim CH, Kim JS, Cho YK, Park JM, Lee IS, Choi MG. Long-term outcomes of palliation for unresectable colorectal cancer obstruction in patients with good performance status: endoscopic stent *vs* surgery. *Surg Endosc* 2016; **30**: 4765-4775 [PMID: 26895922 DOI: 10.1007/s00464-016-4804-2]

6 **Nomoto D**, Baba Y, Akiyama T, Okadome K, Uchihara T, Harada K, Eto K, Hiyoshi Y, Nagai Y, Ishimoto T, Iwatsuki M, Iwagami S, Miyamoto Y, Yoshida N, Watanabe M, Baba H. Outcomes of esophageal bypass surgery and self-expanding metallic stent insertion in esophageal cancer: reevaluation of bypass surgery as an alternative treatment. *Langenbecks Arch Surg* 2020; **405**: 1111-1118 [PMID: 32860110 DOI: 10.1007/s00423-020-01969-x]

7 **Datye A**, Hersh J. Colonic perforation after stent placement for malignant colorectal obstruction--causes and contributing factors. *Minim Invasive Ther Allied Technol* 2011; **20**: 133-140 [PMID: 20929424 DOI: 10.3109/13645706.2010.518787]

8 **Imbulgoda A**, MacLean A, Heine J, Drolet S, Vickers MM. Colonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature review. *Can J Surg* 2015; **58**: 167-171 [PMID: 25799132 DOI: 10.1503/cjs.013014]

9 **Brierley JD**, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Wiley-Blackwell, 2017

10 **Mahoney FI**, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J* 1965; **14**: 61-65 [PMID: 14258950]

11 **Charlson ME**, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987; **40**: 373-383 [PMID: 3558716 DOI: 10.1016/0021-9681(87)90171-8]

**Footnotes**

**Institutional review board statement:** This study was approved by the Institutional Review Board of the University of Tokyo Hospital (No. 2019161NI) and conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

**Informed consent statement:** Informed consent was obtained in the form of opt-out on the website.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 30, 2021

**First decision:** March 7, 2022

**Article in press:** April 22, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Bogach J, Canada; Serban ED, Romania; Tsagkaris C, Switzerland **S-Editor:** Yan JP **L-Editor:** Filipodia **P-Editor:** Yan JP


**Figure Legends**



**Figure 1 Our management of malignant gastrointestinal obstruction.** SEMS:Self-expandable metal stent.



**Figure 2 Flow chart of patient selection.** SEMS:Self-expandable metal stent.



**Figure 3 Kaplan–Meier estimates of overall survival and** **patency duration of the chemotherapy group and the** **best supportive care group.** A: Overall survival; B: Patency duration. BSC: Best supportive care.

**Table 1 Patient characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Chemotherapy (*n* = 470),** ***n* (%)** | **BSC (*n* = 652), *n* (%)** | ***P* value** |
| Age |  |  |  |
| Young (age < 75 yr) | 375 (79.8) | 335 (51.4) | < 0.001 |
| Elder (age ≥ 75 yr) | 95 (20.2) | 317 (48.6) |  |
| Sex |  |  |  |
| Male | 284 (60.4) | 363 (55.7) | 0.112 |
| Female | 186 (39.6) | 289 (44.3) |  |
| Charlson co-morbidity index score |  |  |  |
| < 3 | 175 (37.2) | 343 (52.6) | < 0.001 |
| ≥ 3 | 295 (62.8) | 309 (47.4) |  |
| Barthel index |  |  |  |
| ≥ 60 | 422 (89.8) | 436 (66.9) | < 0.001 |
| < 60 | 27 (5.7) | 153 (23.5) |  |
| Missing | 21 (4.5) | 63 (9.7) |  |
| Medication |  |  |  |
| Aspirin | 18 (3.8) | 33 (5.1) | 0.329 |
| Thienopyridine | 7 (1.5) | 24 (3.7) | 0.027 |
| Warfarin | 8 (1.7) | 20 (3.1) | 0.148 |
| DOACs | 34 (7.2) | 29 (4.4) | 0.045 |
| Other antiplatelet drugs | 7 (1.5) | 33 (5.1) | 0.001 |
| NSAIDs | 293 (62.3) | 314 (48.2) | < 0.001 |
| Steroids | 201 (42.8) | 154 (23.6) | < 0.001 |
| Cancer type |  |  |  |
| Esophageal cancer | 24 (5.1) | 83 (12.7) | < 0.001 |
| Gastric cancer | 151 (32.1) | 113 (17.3) |  |
| Pancreatic cancer | 69 (14.7) | 106 (16.3) |  |
| Colorectal cancer | 146 (31.1) | 212 (32.5) |  |
| Other cancers | 80 (17.0) | 138 (21.2) |  |
| Cancer stage |  |  |  |
| Stage I-III | 81 (17.2) | 157 (24.1) | 0.022 |
| Stage IV or recurrence | 297 (63.2) | 379 (58.1) |  |
| Missing | 92 (19.6) | 116 (17.8) |  |
| Obstruction site |  |  |  |
| Esophageal obstruction | 38 (8.1) | 105 (16.1) | < 0.001 |
| Gastroduodenal obstruction | 189 (40.2) | 233 (35.7) |  |
| Lower gastrointestinal obstruction | 243 (51.7) | 314 (48.2) |  |
| Chemotherapy before the intervention | 274 (58.3) | 413 (63.3) | 0.087 |
| Intervention type |  |  |  |
| Palliative surgery | 294 (62.6) | 283 (43.4) | < 0.001 |
| SEMS placement | 176 (37.4) | 369 (56.6) |  |

BSC: Best supportive care; DOACs: Direct oral anticoagulants; NSAIDs: Non-steroidal anti-inflammatory drugs; SEMS: Self-expandable metal stent.

**Table 2 Factors affecting for overall survival**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Factor** | **Univariate analysis** | | **Multivariate analysis** | |
| **Crude HR (95%CI)** | ***P* value** | **Adjusted HR (95%CI)** | ***P* value** |
| BSC | 1 |  | 1 |  |
| Chemotherapy after the intervention | 0.38 (0.31-0.48) | < 0.001 | 0.36 (0.28-0.46) | < 0.001 |
| Age |  |  |  |  |
| Young (age < 75 yr) | 1 |  | 1 |  |
| Elder (age ≥ 75 yr) | 1.39 (1.10-1.75) | 0.005 | 1.17 (0.92-1.49) | 0.208 |
| Sex |  |  |  |  |
| Male | 1 |  | 1 |  |
| Female | 1.05 (0.84-1.30) | 0.673 | 1.03 (0.83-1.29) | 0.782 |
| Charlson co-morbidity index |  |  |  |  |
| < 3 | 1 |  | 1 |  |
| ≥ 3 | 1.59 (1.27-2.00) | < 0.001 | 1.56 (1.24-1.97) | < 0.001 |
| Barthel index |  |  |  |  |
| ≥ 60 | 1 |  | 1 |  |
| < 60 | 2.16 (1.64-2.84) | < 0.001 | 2.04 (1.53-2.73) | < 0.001 |
| Medication |  |  |  |  |
| Aspirin non-use | 1 |  | 1 |  |
| Aspirin use | 1.01 (0.62-1.64) | 0.980 | 0.81 (0.49-1.33) | 0.399 |
| Thienopyridine non-use | 1 |  | 1 |  |
| Thienopyridine use | 1.32 (0.70-2.47) | 0.391 | 1.07 (0.56-2.03) | 0.843 |
| Warfarin non-use | 1 |  | 1 |  |
| Warfarin use | 0.93 (0.42-2.09) | 0.863 | 0.90 (0.40-2.02) | 0.791 |
| DOACs non-use | 1 |  | 1 |  |
| DOACs use | 1.31 (0.87-1.95) | 0.193 | 1.27 (0.85-1.91) | 0.250 |
| Other antiplatelet drugs non-use | 1 |  | 1 |  |
| Other antiplatelet drugs use | 1.06 (0.60-1.89) | 0.837 | 1.04 (0.58-1.86) | 0.904 |
| NSAIDs non-use | 1 |  | 1 |  |
| NSAIDs use | 0.99 (0.80-1.23) | 0.948 | 1.05 (0.83-1.33) | 0.674 |
| Steroid non-use | 1 |  | 1 |  |
| Steroid use | 1.26 (1.02-1.57) | 0.035 | 1.15 (0.92-1.45) | 0.210 |
| Cancer type |  |  |  |  |
| Esophageal cancer | 1 |  | 1 |  |
| Gastric cancer | 0.68 (0.47-0.99) | 0.045 | 0.64 (0.43-0.96) | 0.030 |
| Pancreatic cancer | 1.00 (0.67-1.48) | 0.991 | 0.92 (0.61-1.39) | 0.697 |
| Colorectal cancer | 0.40 (0.27-0.59) | < 0.001 | 0.47 (0.30-0.73) | < 0.001 |
| Other cancers | 0.77 (0.53-1.13) | 0.186 | 0.78 (0.51-1.18) | 0.242 |
| Cancer stage |  |  |  |  |
| Stage I-III | 1 |  | 1 |  |
| Stage IV or recurrence | 1.96 (1.43-2.70) | < 0.001 | 1.79 (1.28-2.50) | < 0.001 |
| Obstruction site |  |  |  |  |
| Esophageal obstruction | 1 |  | 1 |  |
| Gastroduodenal obstruction | 0.84 (0.61-1.15) | 0.274 | 1.03 (0.58-1.82) | 0.918 |
| Lower gastrointestinal obstruction | 0.48 (0.35-0.66) | < 0.001 | 0.78 (0.42-1.44) | 0.426 |
| Non-chemotherapy before the intervention | 1 |  | 1 |  |
| Chemotherapy before the intervention | 2.08 (1.68-2.57) | < 0.001 | 1.66 (1.31-2.09) | < 0.001 |
| Intervention type |  |  |  |  |
| Palliative surgery | 1 |  | 1 |  |
| SEMS placement | 2.03 (1.63-2.51) | < 0.001 | 1.63 (1.27-2.09) | < 0.001 |

CI: Confidence interval; DOACs: Direct oral anticoagulants; HR: Hazard ratio; NSAIDs: Non-steroidal anti-inflammatory drugs; SEMS: Self-expandable metal stent.

**Table 3 Factors affecting for patency**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Factor** | **Univariate analysis** | | **Multivariate analysis** | |
| **Crude HR (95%CI)** | ***P* value** | **Adjusted HR (95%CI)** | ***P* value** |
| BSC | 1 |  | 1 |  |
| Chemotherapy after the intervention | 0.50 (0.42-0.59) | < 0.001 | 0.49 (0.41-0.59) | < 0.001 |
| Age |  |  |  |  |
| Young (< 75 yr) | 1 |  | 1 |  |
| Elder (≥ 75 yr) | 1.10 (0.92-1.33) | 0.302 | 0.96 (0.79-1.17) | 0.701 |
| Sex |  |  |  |  |
| Male | 1 |  | 1 |  |
| Female | 1.01 (0.85-1.20) | 0.879 | 1.00 (0.84-1.19) | 0.991 |
| Charlson co-morbidity index |  |  |  |  |
| < 3 | 1 |  | 1 |  |
| ≥ 3 | 1.44 (1.21-1.72) | < 0.001 | 1.41 (1.18-1.69) | < 0.001 |
| Barthel index |  |  |  |  |
| ≥ 60 | 1 |  | 1 |  |
| < 60 | 1.57 (1.24-1.97) | < 0.001 | 1.55 (1.22-1.97) | < 0.001 |
| Medication |  |  |  |  |
| Aspirin non-use | 1 |  | 1 |  |
| Aspirin use | 1.00 (0.67-1.49) | 0.992 | 0.82 (0.55-1.24) | 0.350 |
| Thienopyridine non-use | 1 |  | 1 |  |
| Thienopyridine use | 0.89 (0.50-1.58) | 0.700 | 0.77 (0.43-1.37) | 0.367 |
| Warfarin non-use | 1 |  | 1 |  |
| Warfarin use | 0.97 (0.52-1.82) | 0.935 | 0.89 (0.47-1.67) | 0.707 |
| DOACs non-use | 1 |  | 1 |  |
| DOACs use | 1.22 (0.88-1.70) | 0.224 | 1.28 (0.92-1.79) | 0.137 |
| Other antiplatelet drugs non-use | 1 |  | 1 |  |
| Other antiplatelet drugs use | 1.05 (0.66-1.66) | 0.833 | 1.05 (0.66-1.66) | 0.851 |
| NSAIDs non-use | 1 |  | 1 |  |
| NSAIDs use | 0.92 (0.78-1.10) | 0.367 | 1.05 (0.87-1.26) | 0.603 |
| Steroid non-use | 1 |  | 1 |  |
| Steroid use | 1.19 (1.00-1.42) | 0.046 | 1.05 (0.88-1.26) | 0.603 |
| Cancer type |  |  |  |  |
| Esophageal cancer | 1 |  | 1 |  |
| Gastric cancer | 0.86 (0.64-1.16) | 0.321 | 0.98 (0.71-1.34) | 0.888 |
| Pancreatic cancer | 1.11 (0.80-1.52) | 0.531 | 1.18 (0.85-1.64) | 0.324 |
| Colorectal cancer | 0.42 (0.30-0.57) | < 0.001 | 0.67 (0.47-0.95) | 0.024 |
| Other cancers | 0.75 (0.55-1.03) | 0.073 | 0.97 (0.69-1.36) | 0.858 |
| Cancer stage |  |  |  |  |
| Stage I-III | 1 |  | 1 |  |
| Stage IV or recurrence | 1.87 (1.46-2.39) | < 0.001 | 1.65 (1.28-2.14) | < 0.001 |
| Obstruction site |  |  |  |  |
| Esophageal obstruction | 1 |  | 1 |  |
| Gastroduodenal obstruction | 0.88 (0.68-1.13) | 0.325 | 1.22 (0.80-1.88) | 0.356 |
| Lower gastrointestinal obstruction | 0.51 (0.39-0.66) | < 0.001 | 1.30 (0.81-2.08) | 0.269 |
| Non-chemotherapy before the intervention | 1 |  | 1 |  |
| Chemotherapy before the intervention | 2.11 (1.78-2.50) | < 0.001 | 1.64 (1.36-1.98) | < 0.001 |
| Intervention type |  |  |  |  |
| Palliative surgery | 1 |  | 1 |  |
| SEMS placement | 2.84 (2.38-3.39) | < 0.001 | 2.48 (2.03-3.03) | < 0.001 |

CI: Confidence interval; DOACs: Direct oral anticoagulants; HR: Hazard ratio; NSAIDs: Non-steroidal anti-inflammatory drugs; SEMS: Self-expandable metal stent.

**Table 4 Subgroup analysis of the effect of chemotherapy after the intervention on overall survival and patency duration**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Subgroups** | **Overall survival** | | **Patency duration** | |
| **Adjusted HR (95%CI)** | ***P* value** | **Adjusted HR (95%CI)** | ***P* value** |
| All patients | 0.36 (0.28-0.46) | < 0.001 | 0.49 (0.41-0.59) | < 0.001 |
| Age |  |  |  |  |
| Young (< 75 yr) | 0.36 (0.27-0.48) | < 0.001 | 0.48 (0.39-0.60) | < 0.001 |
| Elder (≥ 75 yr) | 0.38 (0.24-0.61) | < 0.001 | 0.52 (0.35-0.76) | < 0.001 |
| Charlson co-morbidity index |  |  |  |  |
| < 3 | 0.43 (0.27-0.68) | < 0.001 | 0.47 (0.33-0.67) | < 0.001 |
| ≥ 3 | 0.31 (0.23-0.41) | < 0.001 | 0.47 (0.37-0.59) | < 0.001 |
| Barthel index |  |  |  |  |
| ≥ 60 | 0.38 (0.29-0.50) | < 0.001 | 0.52 (0.42-0.64) | < 0.001 |
| < 60 | 0.24 (0.11-0.54) | < 0.001 | 0.26 (0.13-0.51) | < 0.001 |
| Cancer type |  |  |  |  |
| Esophageal cancer | 0.45 (0.21-1.00) | 0.049 | 0.80 (0.43-1.49) | 0.479 |
| Gastric cancer | 0.38 (0.24-0.62) | < 0.001 | 0.62 (0.43-0.90) | 0.012 |
| Pancreatic cancer | 0.14 (0.07-0.29) | < 0.001 | 0.28 (0.17-0.45) | < 0.001 |
| Colorectal cancer | 0.45 (0.25-0.78) | 0.005 | 0.45 (0.29-0.70) | < 0.001 |
| Obstruction site |  |  |  |  |
| Esophageal obstruction | 0.46 (0.23-0.92) | 0.028 | 0.80 (0.47-1.37) | 0.425 |
| Gastroduodenal obstruction | 0.26 (0.18-0.39) | < 0.001 | 0.37 (0.28-0.50) | < 0.001 |
| Lower gastrointestinal obstruction | 0.44 (0.30-0.64) | < 0.001 | 0.51 (0.38-0.69) | < 0.001 |
| Intervention type |  |  |  |  |
| Palliative surgery | 0.34 (0.24-0.48) | < 0.001 | 0.39 (0.29-0.52) | < 0.001 |
| SEMS placement | 0.37 (0.26-0.52) | < 0.001 | 0.54 (0.42-0.70) | < 0.001 |

CI: Confidence interval; HR: Hazard ratio; SEMS: Self-expandable metal stent.

**Table 5 Adverse events**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Chemotherapy (*n* = 470),** ***n* (%)** | **BSC (*n* = 652), *n* (%)** | ***P* value** |
| Perforation | 6 (1.3) | 6 (0.9) | 0.567 |
| Gastrointestinal bleeding | 7 (1.5) | 3 (0.5) | 0.105 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**